Tebipenem Pivoxil
Phase 2Small molecule
Tebipenem Pivoxil is one of 12 small molecule programs targeting Shigellosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Shigellosis
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Bacteriophage
AAdaptive Phage Therapeutics, Inc.
Phase 2
MR-Vac
GSKPhase 2
TYPHIBEV
GSKPhase 2
Gsk's Investigational Vaccine 692342
GSKPhase 1
Ceftriaxon
IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 2
Tebipenem Pivoxil
IInternational Centre for Diarrhoeal Disease Research, Bangladesh
Phase 2
Altsonflex1-2-3
GSKPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Shigellosis1 trial
Tebipenem Trial in Children With Shigellosis
Active, not recruiting·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 2·NCT05121974·132 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tebipenem Pivoxil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details